WallStSmart

Abbott Laboratories (ABT)vsPDD Holdings Inc. (PDD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

PDD Holdings Inc. generates 844% more annual revenue ($418.54B vs $44.33B). PDD leads profitability with a 24.4% profit margin vs 14.7%. PDD appears more attractively valued with a PEG of 1.03. PDD earns a higher WallStSmart Score of 77/100 (B+).

ABT

Buy

51

out of 100

Grade: C-

Growth: 5.3Profit: 6.5Value: 7.3Quality: 4.8
Piotroski: 3/9

PDD

Strong Buy

77

out of 100

Grade: B+

Growth: 8.0Profit: 8.5Value: 10.0Quality: 8.5
Piotroski: 4/9Altman Z: 3.53
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-315.5%)

Margin of Safety

-315.5%

Fair Value

$25.23

Current Price

$104.83

$79.60 premium

UndervaluedFair: $25.23Overvalued
PDDUndervalued (+67.8%)

Margin of Safety

+67.8%

Fair Value

$332.33

Current Price

$102.61

$229.72 discount

UndervaluedFair: $332.33Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT3 strengths · Avg: 8.3/10
Market CapQuality
$180.82B9/10

Large-cap with strong market position

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Free Cash FlowQuality
$2.63B8/10

Generating 2.6B in free cash flow

PDD6 strengths · Avg: 9.8/10
P/E RatioValuation
9.8x10/10

Attractively priced relative to earnings

Return on EquityProfitability
30.5%10/10

Every $100 of equity generates 31 in profit

Debt/EquityHealth
0.0310/10

Conservative balance sheet, low leverage

Free Cash FlowQuality
$45.66B10/10

Generating 45.7B in free cash flow

Altman Z-ScoreHealth
3.5310/10

Safe zone — low bankruptcy risk

Market CapQuality
$139.25B9/10

Large-cap with strong market position

Areas to Watch

ABT4 concerns · Avg: 3.8/10
PEG RatioValuation
1.524/10

Expensive relative to growth rate

P/E RatioValuation
28.1x4/10

Moderate valuation

Revenue GrowthGrowth
4.4%4/10

4.4% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PDD0 concerns · Avg: 0/10

No major concerns identified

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : PDD

The strongest argument for PDD centers on P/E Ratio, Return on Equity, Debt/Equity. Profitability is solid with margins at 24.4% and operating margin at 23.1%. PEG of 1.03 suggests the stock is reasonably priced for its growth.

Bear Case : ABT

The primary concerns for ABT are PEG Ratio, P/E Ratio, Revenue Growth.

Bear Case : PDD

No major red flags identified for PDD, but monitor valuation.

Key Dynamics to Monitor

ABT profiles as a value stock while PDD is a mature play — different risk/reward profiles.

ABT carries more volatility with a beta of 0.74 — expect wider price swings.

PDD is growing revenue faster at 9.0% — sustainability is the question.

PDD generates stronger free cash flow (45.7B), providing more financial flexibility.

Bottom Line

PDD scores higher overall (77/100 vs 51/100), backed by strong 24.4% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

PDD Holdings Inc.

CONSUMER CYCLICAL · INTERNET RETAIL · China

Pinduoduo Inc., operates an electronic commerce platform in the People's Republic of China. The company is headquartered in Shanghai, the People's Republic of China.

Visit Website →

Want to dig deeper into these stocks?